Medtronic CoreValve Evolut R U.S. Clinical Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 241 participants.

Also called NCT02207569

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 241 participants (enrolled count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02207569
Other papers using this trial's data
  • Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study JACC. Cardiovascular interventions, 2017-02-13 DOI, PubMed 28183466

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02207569. Allocation not applicable; no masking; primary purpose treatment. Start 2014-08 (registry gives no type); primary completion 2015-08 (actual). Results posted on 2017-12-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Medtronic CoreValve Evolut R U.S. Clinical Study
Condition
Aortic Stenosis
Intervention (Device)
CoreValve Evolut R TAVR system
Lead sponsor
Medtronic Cardiovascular (class: industry)

Record details

Record id
cardio:ct-nct02207569
Content hash
114fa4deb39f5de71b30f8448605eaaed522956c49893edb46055e6f4fb077be